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Abstract
A new family of ruthenium(II) complexes with sterically expansive ligands for targeting DNA
defects was prepared, and their luminescent responses to base pair mismatches and/or abasic sites
were investigated. The design of the complexes sought to combine the mismatch specificity of
sterically expansive metalloinsertors, such as [Rh(bpy)2(chrysi)]3+ (chrysi = chrysene-5,6-quinone
diimine), and the light switch behavior of [Ru(bpy)2(dppz)]2+ (dppz = dipyrido[3,2-a:2′,3′-
c]phenazine). In one approach, complexes bearing analogues of chrysi incorporating hydrogen-
bonding functionality similar to dppz were synthesized. While the complexes show luminescence
only at low temperatures (77 K), competition experiments with [Ru(bpy)2(dppz)]2+ at ambient
temperatures reveal that the chrysi derivatives preferentially bind DNA mismatches. In another
approach, various substituents were introduced onto the dppz ligand to increase its steric bulk for
mismatch binding while maintaining planarity. Steady state luminescence and luminescence
lifetime measurements reveal that these dppz derivative complexes behave as DNA “light
switches,” but that the selectivity in binding and in luminescence with mismatched/abasic versus
well-matched DNA is not high. In all cases, the luminescence depends sensitively upon structural
perturbations to the dppz ligand.
INTRODUCTION
Deficiencies in the DNA mismatch repair pathway, which corrects DNA defects including
base pair mismatches and single base bulges, are associated with several forms of human
cancer.1–3 Our laboratory has been interested in developing octahedral metal complexes that
target DNA defects.4–8 Since deficiencies in mismatch repair necessarily lead to an
increased frequency of DNA defects within the cell, targeting these defects with small metal
complexes provides a new strategy in designing new cancer diagnostics and
chemotherapeutics.
We have reported octahedral rhodium complexes that specifically bind single base mismatch
sites in DNA and, upon photoactivation, cleave the DNA backbone.4–6 The Rh complex
[Rh(bpy)2(chrysi)]3+ (Figure 1) recognizes 80% of mismatched sites in all sequence
contexts and selectively targets a single base mismatch in a 2725 base pair DNA plasmid.5
Structural studies of the rhodium complex bound to mismatched DNA reveal that it inserts
into the destabilized mismatch site from the minor groove with complete ejection of the
mismatched base pair into the major groove and no change in base pair rise.9 Thus, the
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[Rh(bpy)2(chrysi)]3+ complex is a metalloinsertor rather than a classical metallointercalator.
Furthermore, we have demonstrated that abasic sites and single base bulges are also
recognized by the [Rh(bpy)2(chrysi)]3+ complex.10 The source of defect-specific binding is
the chrysi inserting ligand. Structural properties of the chrysi ligand (e.g., steric bulk and
planarity) make it too wide to intercalate into well-matched duplex DNA, but it is well
suited to bind to destabilized sites in DNA. The binding affinity of this rhodium complex to
each mismatch is correlated with the thermodynamic stability of the mismatch.
Another effort in our laboratory has been constructing metal complexes as luminescent
probes for DNA.8 The complex [Ru(bpy)2(dppz)]2+ (Figure 1, bpy = 2,2′-bipyridine)
exhibits light switch behavior in the presence of well-matched DNA.8 The luminescence of
this complex is quenched in aqueous solvents due to the formation of hydrogen bonding
interactions between solvent molecules and the phenazine nitrogen atoms of the dppz
ligand.8,11,12 The Ru complex luminesces intensely in the presence of DNA, however,
because the phenazine moiety is protected from the quenching environment upon
intercalation into the duplex.8,11,12 Steady state luminescence spectra, excited state lifetime
measurements, and NMR studies demonstrate that the [Ru(bpy)2(dppz)]2+ complex
intercalates into DNA by one of two binding modes: side-on or perpendicular.8,11,13 In the
perpendicular mode, the Ru–dppz axis lies along the DNA dyad axis, protecting the
phenazine fragment from water. In the side-on mode, the Ru–dppz axis lies along the long
axis of the base stack, partially exposing the ligand to solvent. Thus, complexes bound in the
better-protected perpendicular intercalation mode show greater luminescent enhancement
upon binding to DNA and have longer excited state lifetimes than those in the side-on mode.
Recent crystal structures have shown intercalation of dppz complexes into the DNA duplex
from the minor groove,14–15 though NMR studies have pointed to intercalation from the
major groove;13 the energetic differences between major and minor groove orientations
must be small.
How might the luminescent properties of the [Ru(bpy)2(dppz)]2+ complex change in the
presence of DNA containing a defect? Previously, we have shown that [Ru(bpy)2(dppz)]2+,
while showing luminescence bound to duplex DNA, shows still greater luminescence in the
presence of a mismatch.16 More recent efforts to understand how mismatches affect
[Ru(bpy)2(dppz)]2+ binding have led to the determination of an atomic-resolution crystal
structure of Δ-[Ru(bpy)2(dppz)]2+ bound to a mismatch-containing oligonucleotide.14 The
structure reveals that, like its rhodium counterpart, the ruthenium complex also recognizes
the destabilized mismatches through metalloinsertion: the dppz ligand inserts into the base
stack from the minor groove, extruding the mispaired bases out of the helix. Thus, it is
conceivable that by combining the structural features of [Rh(bpy)2(chrysi)]3+ (for mismatch-
specific recognition) and [Ru(bpy)2(dppz)]2+ (for luminescence), it might be possible to
develop an improved luminescent reporter for DNA defects. Here, we have investigated two
approaches for enhancing the mismatch-specificity: (i) the replacement of the dppz ligand
with sterically expansive inserting ligands, such as chrysi, and (ii) the incorporation of
various functionalities onto the dppz ligand to increase the steric bulk. We report the
preparation of a new family of [Ru(bpy)2(L)]2+ derivatives (Figure 2) and the luminescent
behavior of each derivative in the presence of duplex DNA with and without defects.
Experimental Procedures
Materials and Methods
All reagents and solvents were purchased from commercial suppliers and used without
further purification. Chrysene-5,6-quinone and benzo[a]phenazine-5,6-quinone were
synthesized according to literature procedures.17 The Ru complexes, Ru(bpy)2Cl2,
[Ru(bpy)2(dppz)](X)2 (15) and [Ru(bpy)2(tactp)](X)2 (18, X = PF6 or Cl) were prepared by
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previously described procedures.8,18–19 UV-visible spectra were recorded on a Beckman DU
7400 UV-visible spectrophotometer (Beckman Coulter). The oligonucleotides 5′-GAC CAG
CTT ATC ACC CCT AGA TAA GCG-3′ and 3′-CTG GTC GAA TAG TXG GGA TCT
ATT CGC-5′ [X = G (M), C (MM) or R (AB, R denotes a tetrahydrofuranyl abasic site)]
were synthesized on an ABI 3400 DNA synthesizer (Applied Biosystems) or purchased
from Integrated DNA Technologies and purified as previously reported.20
Synthesis
1,2-Dihydrobenz[c]acridine (1)—This compound was synthesized according to the
literature procedure21 and purified by SiO2 column chromatography (9:1 hexane/EtOAc).
Yield: 57%. 1H NMR (CDCl3, 300 MHz, δ(ppm)): 8.60 (d, 3J = 7.4 Hz, 1H), 8.17 (d, 3J =
8.3 Hz, 1H), 7.95 (s, 1H), 7.77 (d, 3J = 8.1 Hz, 1H), 7.67 (t, 3J = 7.6 Hz, 1H), 7.59 – 7.33
(m, 3H), 7.33 – 7.25 (m, 1H), 3.15 (t, 3J = 6.5 Hz, 2H), 3.03 (t, 3J = 6.5 Hz, 2H). ESI(+)MS
(m/z) for [M+H]+ calcd: 232.1, found: 232.4.
5,6-Dihydronaphtho[1,2-b][1,8]naphthyridine (2)—A suspension of α-tetralone (0.39
g, 2.7 mmol), (2-aminopyridin-3-yl)methanol22 (0.33 g, 2.6 mmol), benzophenone (0.48 g,
2.6 mmol) and potassium tert-butoxide (0.30 g, 2.7 mmol) in dry dioxane (10 mL) was
heated under reflux under an Ar atmosphere for 2 hr. The red suspension was cooled to
room temperature, filtered through Celite and poured into a saturated NH4Cl solution (20
mL). This was extracted with EtOAc (3 × 20 mL) and the combined organic layers were
dried over Na2SO4, filtered and the solvent was removed. The crude material was purified
by SiO2 column chromatography (1:1 hexane/EtOAc) to give 2 as a pale red solid (0.37 g,
61%). 1H NMR (CDCl3, 300 MHz, δ(ppm)): 9.06 (dd, 3J = 4.2 Hz, 4J = 1.8 Hz, 1H), 8.84 –
8.73 (m, 1H), 8.20 – 8.05 (m, 1H), 7.95 (s, 1H), 7.50 – 7.35 (m, 3H), 7.33 – 7.23 (m, 1H),
3.29 – 3.09 (m, 2H), 3.10 – 2.96 (m, 2H). ESI(+)MS (m/z): [M+H]+ calcd: 233.1, found:
233.4; [2M+Na]+ calcd: 487.2, found: 486.9.
Ligand 3 – 4 synthesis—A solution of 1 or 2 (2.0 mmol) in 1:1 acetic acid/acetic
anhydride (10 mL) was cooled in an ice bath (Scheme 1). A solution of Na2Cr2O7 (0.90 g,
3.0 mmol) in 1:1 acetic acid/acetic anhydride (10 mL) was added dropwise and the reaction
mixture was allowed to warm to room temperature. The reaction was stirred at room
temperature for 8 days, during which time a yellow solid precipitated from the reaction
mixture. The yellow precipitate was filtered, washed with H2O and dried.
Benz[c]acridine (acri) quinone (3)23—Yield: 81%. 1H NMR (CDCl3, 300 MHz,
δ(ppm)): 9.07 – 8.87 (m, 2H), 8.25 (t, 3J = 8.1 Hz, 1H), 8.19 (d, 3J = 8.4 Hz, 1H), 7.98 (d, 3J
= 8.1 Hz, 1H), 7.89 (dd, 3J = 16.4, 8.1 Hz, 2H), 7.64 (t, 3J = 7.4 Hz, 2H). ESI(+)MS (m/z)
for [2M+Na]+ calcd: 541.1, found: 540.8.
5,6-Naphtho[1,2-b][1,8]naphthyridine (naphthi) quinone (4)—Yield: 69%. 1H
NMR (CDCl3, 300 MHz, δ(ppm)): 9.29 (dd, 3J = 4.1 Hz, 4J = 1.8 Hz, 1H), 9.11 (d, 3J = 7.9
Hz, 1H), 9.06 (s, 1H), 8.38 (dd, 3J = 8.1 Hz, 4J = 1.7 Hz, 1H), 8.30 (d, 3J = 7.6 Hz, 1H),
7.91 (t, 3J = 7.4 Hz, 1H), 7.69 (t, 3J = 7.5 Hz, 1H), 7.62 (dd, 3J = 8.1, 4.2 Hz, 1H).
ESI(+)MS (m/z) for [M+CH3OH+H]+ calcd: 293.1, found: 293.1.
3,6-diethynylbenzene-1,2-diamine (7)—A solution of 4,7-diethynylbenzo[c][1,2,5]-
thiadiazole24 (200 mg, 1.1 mmol) in 30 mL THF was purged with Ar for 30 min and cooled
to 0 °C. Eight equivalents of LiAlH4 (in THF) were added dropwise over 10 min. The
resulting solution was stirred for 10 min at 0 °C and allowed to warm slowly to room
temperature. The reaction was quenched by addition of water after stirring for 4 h at room
temperature, and the solution was filtered. The filtrate was extracted with CH2Cl2 (three
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times). After removal of CH2Cl2, the crude product was purified by SiO2 column
chromatography with a solvent gradient (50%:50% Hx:CH2Cl2 to 100% CH2Cl2) to obtain
the desired product 7 (153 mg, 0.98 mmol, 89%). 1H NMR (CDCl3, 300 MHz, δ(ppm)):
6.82 (s, 2H), 3.98 (br, s, 4H), 3.44 (s, 2H). HREI (m/z) for M+ calcd: 156.0687, found:
156.0687.
1,4-Dibromo-2,3-diaminonaphthalene (9)—was synthesized according to reported
procedures.25
Dppz derivatives—Ligands were synthesized by refluxing 5 – 9 (0.63 mmol) with 1,10-
phenanthroline-5,6-dione, and 10 or 11 with 5,6-diamino-1,10-phenanthroline26 (0.63
mmol) in ethanol (10 mL) for 8 h, as shown in Scheme 2.8d The yellow precipitates were
collected, washed with cold ethanol (three times, 20 mL), dried under vacuum, and used for
preparation of the Ru complexes without further purification.
Dppa. Yield: 86%. ESI(+)MS (m/z) for [M+H]+ calcd: 327.1, found: 327.2.
Dppae. Yield: 40%. ESI(+)MS (m/z) for [M+H]+ calcd: 331.1, found: 331.2.
Dppn. Yield: 83%. ESI(+)MS (m/z) for [M+H]+ calcd: 333.1, found: 333.1.
Br2dppn. Yield: 75%. ESI(+)MS (m/z) for [M+H]+ calcd: 490.9, found: 491.0.
pyrene-phen. Yield: 90%. ESI(+)MS (m/z) for [M+H]+ calcd: 407.1, found: 407.3.
[Ru(bpy)2(NH3)2](PF6)2—A solution of Ru(bpy)2Cl2 (0.47 g, 0.9 mmol) and NH4OH (10
mL) in MeOH (5 mL) was heated at 60 °C for 4 h. The reaction mixture was cooled to room
temperature and the solvent was removed in vacuo. The residue was redissolved in MeOH
and precipitated with Et2O. The solid was collected, redissolved in water (10 mL) and
excess NH4PF6 (s) was added. The suspension was stirred in the absence of light for 1 h,
filtered and the red precipitate was washed with cold water (15 mL), Et2O (3 × 10 mL) and
dried under vacuum to give [Ru(bpy)2(NH3)2](PF6)2 (0.58 g, 0.8 mmol, 88%). 1H NMR
(CD3OD, 300 MHz, δ(ppm)): 9.18 (d, 3J = 5.6 Hz, 2H), 8.64 (d, 3J = 8.1 Hz, 2H), 8.46
(d, 3J = 8.1 Hz, 2H), 8.20 (t, 3J = 7.9 Hz, 2H), 7.82 (t, 3J = 7.7 Hz, 4H), 7.65 (d, 3J = 5.7 Hz,
2H), 7.27 – 7.08 (m, 2H), 2.89 (s, 6H).
[Ru(bpy)2(L)]2+ complexes—Method 1: a suspension of [Ru(bpy)2(NH3)2](PF6)2
(0.043 mmol) and NaH (0.8 mmol) in dry MeCN (10 mL) was deoxygenated and stirred
under an Ar atmosphere for 30 mins. The ligand (0.048 mmol) was added, the mixture was
deoxygenated and stirred at room temperature for 4 h before quenching the reaction with a
couple of drops of 1 M HCl. The reaction mixture was diluted with water (10 mL), excess
NH4PF6 (s) was added and the solution was concentrated in vacuo. The precipitates were
collected and washed with water (2 × 10 mL) then converted to the soluble chloride salt by
anion exchange chromatography (Sephadex QAE). The residues were purified on a Waters
C18 sep-pak cartridge and by preparative HPLC using a gradient of H2O (with 0.1% TFA) to
CH3CN over 60 min. The complex was converted to the chloride salt by anion exchange
chromatography (Sephadex QAE).
[Ru(bpy)2(chrysi)](X)2 (12, X = TFA or Cl): Yield: 18%. 1H NMR (CD3CN, 300 MHz,
δ(ppm)): 12.91 (s, 1H), 12.42 (s, 1H), 8.58 – 8.44 (m, 7H), 8.39 – 8.30 (m, 1H), 8.24 (d, 3J =
8.8 Hz, 1H), 8.19 – 8.03 (m, 5H), 7.94 (d, 3J = 5.6 Hz, 2H), 7.82 (t, 3J = 8.3 Hz, 1H), 7.73 –
7.59 (m, 5H), 7.54 – 7.39 (m, 4H). ESI(+)MS (m/z): [M−H]+ calcd: 669.1, found: 669.1;
[M]2+ calcd: 335.1, found: 334.6. UV-vis in H2O, λabs/nm (ε × 104/M−1 cm−1): 255 (11.5),
282 (14.5), 550 (6.4).
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[Ru(bpy)2(acri)](X)2 (13, X = TFA or Cl): Yield: 22%. 1H NMR (CD3CN, 300 MHz,
δ(ppm)): 14.06 (s, 1H), 13.07 (s, 1H), 9.75 (s, 1H), 9.12 (dd, 3J = 8.1 Hz, 4J = 1.4 Hz, 1H),
8.60 – 8.44 (m, 5H), 8.19 (d, 3J = 8.6 Hz, 1H), 8.13 – 8.00 (m, 7H), 7.97 – 7.84 (m, 1H),
7.83 (t, 3J = 7.6 Hz, 1H), 7.76 – 7.59 (m, 4H), 7.54 – 7.37 (m, 4H). ESI(+)MS (m/z): [M
−H]+ calcd: 670.1, found: 670.3; [M]2+ calcd: 335.6, found: 335.7. UV-vis in H2O, λabs/nm
(ε × 104/M−1 cm−1): 238 (5.1), 285 (8.2), 400 (1.1), 438 (1.2), 542 (3.7).
[Ru(bpy)2(naphthi)](X)2 (14, X = TFA or Cl): Yield: 4%. 1H NMR (CD3CN, 300 MHz,
δ(ppm)): 13.76 (s, 1H), 12.79 (s, 1H), 9.62 (s, 1H), 9.21 (dd, 3J = 4.1 Hz, 4J = 1.9 Hz, 1H),
9.08 (d, 3J = 7.4 Hz, 1H), 8.58 – 8.38 (m, 6H), 8.07 (dd, 3J = 16.0, 8.0 Hz, 6H), 7.89 – 7.58
(m, 5H), 7.54 – 7.31 (m, 4H). ESI(+)MS (m/z): [M−H]+ calcd: 671.1, found: 671.2; [M]2+
calcd: 336.1, found: 335.4. UV-vis in H2O, λabs/nm (ε × 104/M−1 cm−1): 241 (4.6), 288
(6.8), 425 (1.1), 540 (2.7).
Method 2: ethylene glycol (7 mL) was added to a mixture of Ru(bpy)2Cl2 (0.069 mmol) and
the dppz derivatives (0.069 mmol), and the solution was heated to 130 C for 12 h (Scheme
3). After cooling the reaction mixture to room temperature, the solution was diluted with
water (7 mL) followed by the addition of excess NH4PF6 (s). The orange precipitates were
collected, washed with water (3 × 5 mL), and dried under vacuum. The complexes were
recrystallized by addition of Et2O into their CH3CN solutions at room temperature and
afterward converted to the soluble Cl salt by anion exchange chromatography (Sephadex
QAE). They were further purified by preparative HPLC using a gradient of H2O (with 0.1%
TFA) to CH3CN (with 0.1% TFA) over 30 min.
[Ru(bpy)2(dppa)](X)2 (16, X = PF6 or Cl): Yield: 63%. 1H NMR (CD3CN, 500 MHz,
δ(ppm)): 9.76–9.68 (m, 2H), 9.06 (m, 1H), 8.70 (m, 1H), 8.59–8.54 (m, 4H), 8.49 (1H, m),
8.22 (s, br, 2H), 8.14 (m, 2H), 8.05 (m, 2H), 7.94 (m, 2H), 7.89 (m, 2H), 7.79 (2H, m), 7.49
(m, 2H), 7.30 (m, 2H). ESI(+)MS (m/z): [M-2(PF6)]2+ calcd. 370.1, found 370.0; [M-PF6]+
calcd. 885.1, found 885.2. UV-vis in H2O, λabs/nm (ε × 104/M−1 cm−1): 284 (10), 362 (1.9),
378 (1.9), 444 (1.6).
[Ru(bpy)2(dppae)](X)2 (17): The Ru complex was prepared as described above. The crude
product was purified via preparative TLC (silica, 4:4.5:1, CH3CN:water:NH4Cl (sat, aq))
followed by preparative HPLC (a gradient of H2O with 0.1% TFA to CH3CN with 0.1%
TFA). The Cl salt was then obtained using anion exchange chromatography on Sephadex
QAE. Yield: 20%. ESI(+)MS (m/z): [M-2(Cl)]2+ calcd. 372.1, found 372.0. UV-vis in H2O,
λabs/nm (ε × 104/M−1 cm−1): 244 (4.3), 272 (sh, 4.7), 288 (6.3), 306 (4.3), 364 (1.2), 380
(1.5), 426 (1.4), 440 (1.3).
[Ru(bpy)2(dppn)](X)2 (19): Yield: 72%. 1H NMR (CD3CN, 500 MHz, δ(ppm)): 9.71–
9.681 (m, 2H), 9.17–9.16 (m, 2H), 8.57 (dd, J = 8.0 Hz, 4H), 8.41–8.39 (m, 2H), 8.18–8.14
(m, 4H), 8.10–8.05 (m, 2H), 7.94–7.88 (m, 4H), 7.82–7.78 (m, 4H), 7.52–7.49 (m, 2H),
7.34–7.31 (m, 2H). ESI(+)MS (m/z): [M-2(PF6)]2+ calcd. 373.1, found 373.1; [M-PF6]+
calcd. 891.1, found 891.2. UV-vis in H2O, λabs/nm (ε × 104/M−1 cm−1): 244 (5.3), 286 (7.0),
324 (7.4), 390 (1.6), 412 (2.2), 442 (2.0).
[Ru(bpy)2(Br2dppn)](X)2 (20): Yield: 69%. 1H NMR (CD3CN, 500 MHz, δ(ppm)): 8.43–
8.41 (m, 2H), 7.49–7.46 (m, 2H), 7.43–7.39 (m, 4H), 6.96–6.94 (m, 2H), 6.87–6.84 (m, 2H),
6.79–6.76 (m, 2H), 6.66–6.55 (m, 8H), 6.23 (2H, m), 6.06 (2H, m). ESI(+)MS (m/z):
[M-2(PF6)]2+ calcd. 451.0, found 451.0; [M-PF6]+ calcd. 1049.3, found 1049.1. UV-vis in
H2O, λabs/nm (ε × 104/M−1 cm−1): 254 (3.7), 286 (4.5), 324 (4.3), 396 (1.0), 420 (1.4), 446
(1.4).
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[Ru(bpy)2(pyrene-phen)](X)2 (21): Yield: 76%. 1H NMR (CD3CN, 500 MHz, δ(ppm)):
9.71 (d, 3J = 7.5 Hz, 2H), 9.47 (d, 3J = 7.5 Hz, 2H), 8.59 (t, 3J = 9.3 Hz, 4H), 8.27–8.23 (m,
4H), 8.19–8.11 (m, 4H), 8.06 (td, 3J = 8.0 Hz, 4J = 1.2 Hz, 2H), 8.0–7.92 (m, 4H), 7.84
(d, 3J = 5.1 Hz, 2H), 7.74 (s, 2H), 7.52 (m, 2H), 7.34 (m, 2H). ESI(+)MS (m/z):
[M-2(PF6)]2+ calcd. 410.8, found 410.2; [M-PF6]+ calcd. 965.1, found 965.4. UV-vis in
H2O, λabs/nm (ε × 104/M−1 cm−1): 236 (3.7), 288 (5.0), 348 (1.1), 452 (1.3), 476 (1.3).
Luminescence Measurements
Steady state fluorescence—Luminescence spectra were recorded on an ISS-K2
spectrofluorometer in 5 mM Tris, 50 mM NaCl, pH 7.5 at ambient temperature or in a 10 M
LiCl glass at 77 K in aerated solutions. Samples were excited at 440 nm and the emission
intensity was integrated from 560 to 800 nm.
Excited state lifetime measurements—Samples were excited using a Nd:YAG-
pumped OPO (Spectra-Physics Quanta-Ray). Laser power at 470 nm ranged from 3.0–4.5
mJ per pulse at 10 Hz. Emitted light was collected and focused onto the entrance slit of an
ISA double grating (100 mm) monochromator and detected by a PMT (Hamamatsu R928).
Each measurement is the average of 500 or 1000 shots of 8 ns duration. Emission decays
were fit to mono- or bi-exponential functions using non-linear least squares minimization.
RESULTS AND DISCUSSION
Design considerations
Inspired by the activity of [Rh(bpy)2(chrysi)]3+ and [Ru(bpy)2(dppz)]2+ (Figure 1) toward
DNA,4–10,13–14,16 we aimed to develop a new framework for detecting DNA defects based
on luminescence. The key feature of the chrysi complex that enables it to specifically bind to
destabilized sites in DNA is the sterically expansive inserting chrysi ligand.4–7,9,10
Meanwhile, the luminescence-based detection of DNA by [Ru(bpy)2(dppz)]2+ is based on
the protection of the dppz ligand from water by the DNA duplex.8,13 Thus, by combining
the characteristics of chrysi and dppz into a single ligand, it may be possible to create a Ru
complex that luminesces only when specifically bound to DNA defects. Guided by these
design considerations, a series of ruthenium complexes, based on the structures of both
[Rh(bpy)2(chrysi)]3+ and [Ru(bpy)2(dppz)]2+ using two strategies, were prepared as
candidate luminescent reporters for DNA defects (Figure 2). In one approach, sterically
expansive chrysi analogues with hydrogen bonding functionality similar to the dppz ligand
were investigated. The chrysi parent complex was also studied as a comparison; this
complex was not expected to show “light-switch” behavior but specificity in binding a
mismatch was expected due to the ligand expanse.
In the second approach, simple substitutions (CO2H, acetylene, Br, and phenyl) were
incorporated onto the dppz ligand in order to increase its width, length, or both (Figure 2).
For example, the wider ligand framework in pyrene-phen and tactp is similar to that of the
sterically bulky chrysi ligand. As dppn is longer than dppz, [Ru(bpy)2(dppn)]2+ will likely
bind to well-matched sites from the major groove rather than the minor groove leading to
greater exposure of the phenazine nitrogen atoms to solvent compared to dppz, thus
reducing luminescence. Therefore, because of the likelihood of low luminescence when
bound to well-matched DNA, complexes with dppn (or dppa) might show a significant
increase in luminescence due only to selective intercalation or insertion into destabilized
lesion sites in DNA. Alternatively, increasing the width of the dppz ligand to make dppae or
tactp was expected to discourage the binding of the complex to well-matched DNA in a
similar fashion to the sterically expansive chrysi ligand. Increasing both the length and
width (to make Br2dppn and pyrene-phen) would then combine the effects.
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Synthesis of the Ru complexes
Ligands 1 and 2 were synthesized in two steps from α-tetralone by a Friedländer synthesis
and subsequent oxidation with sodium dichromate (Scheme 1).21,23 The ruthenium
complexes 12 – 14 were synthesized by reacting [Ru(bpy)2(NH3)2](PF6)2 with the
appropriate quinone ligand in the presence of sodium hydride at ambient temperature
(Scheme 3). Complexes 12 – 14 were isolated in 4–20% yield following purification and
anion exchange to the chloride salt. Unexpectedly, [Ru(bpy)2(phzi)]2+ (Figure 2) was not the
major product from the reaction with benzo[a]phenazine-5,6-quinone and was only isolated
in trace amounts, as characterized by HPLC and mass spectrometry. We propose that
[Ru(bpy)2(iqi)]2+ (22) (Figure S1) is the major product of the reaction as the 1H NMR
spectrum of the isolated complex only contains one imine proton signal and the mass
spectrum is consistent with loss of carbon monoxide. It has been reported that a related
ligand, 1,10-phenanthroline- 5,6-dione, loses carbon monoxide under basic conditions.27
Similar ligand decomposition in the presence of sodium hydride during the course of the
reaction could account for the low yields of complexes 12 – 1428 and the formation of
byproduct 22. Following the loss of carbon monoxide from benzo[a]phenazine-5,6-quinone,
unlike the other ligands, it is still possible to coordinate to the metal center in a bidentate
fashion through the phenazine nitrogen and imine formed from the remaining quinone.
The Ru complexes [Ru(bpy)2(dppz)]2+ (15) and [Ru(bpy)2(tactp)]2+ (18) were prepared by
previously published methods.8,19 For the ligands dppa, dppae, dppn, and Br2dppn (Scheme
2), the amine moieties were condensed with 1,10-phenanthroline-5,6- dione in
ethanol.8d,24,25 The pyrene-phen ligand was obtained by condensation of pyrene-4,5-dione
and 5,6-diamino-1,10-phenanthroline26 in ethanol.8d The complexes (16, 17, and 19 – 21)
were obtained by refluxing a solution containing Ru(bpy)2Cl2 and 1 equivalent of the
corresponding dppz derivative in ethylene glycol at 130 °C for 8 h, as depicted in Scheme 3.
Addition of excess NH4PF6 (s) into the reaction solution of 1:1 ethylene glycol:water
allowed the isolation of the Ru complexes as PF6 salts, followed by purification via
recrystallization or column chromatography. All complexes show the characteristic MLCT
transition absorption in the visible region at ~440 nm.
Luminescent characteristics of the Ru complexes with and without DNA
While complexes 12 – 14 (Scheme 3 and Figure 2) are not luminescent at ambient
temperature in various solvents (dry MeCN, Tris buffer and 10 M LiCl),
[Ru(bpy)2(chrysi)]2+ (12) and [Ru(bpy)2(naphthi)] 2+ (14) are luminescent in the absence of
DNA at 77 K in a 10 M LiCl glass (Figure 3). In the presence of DNA, there is no
luminescence differential between mismatched and matched DNA for both complexes.
[Ru(bpy)2(acri)]2+ (13) is not luminescent at 77 K in dry MeCN nor in the presence or
absence of DNA in 10 M LiCl upon excitation at 440 nm. The DNA “light switch” complex
[Ru(bpy)2(dppz)]2+ (15) is also luminescent at 77 K in the absence of DNA (Figure S2).
Therefore, it is not possible to determine the mismatch specificity or light switch behavior of
the complexes from low temperature experiments.
At ambient temperature, [Ru(bpy)2(chrysi)]2+ (12), [Ru(bpy)2(acri)]2+ (13), and
[Ru(bpy)2(naphthi)]2+ (14) are not luminescent in the absence or presence of DNA.
Therefore, competition experiments were carried out with the “light switch” complex
[Ru(bpy)2(dppz)]2+ (15), in order to investigate the room temperature mismatch specificity
of the complexes. Control experiments reveal that complexes 12 – 14 do not quench the
luminescence of 15 in the absence of DNA in dry MeCN (Figure S3). The luminescence of
1:1 DNA/15 mixtures in aqueous buffer was measured upon addition of up to ten
equivalents of complexes 12 – 14. A decrease in the luminescence is expected if the
complex displaces 15, as 15 is luminescent only when bound to DNA. For all three
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complexes 12 – 14, there was a small decrease in the luminescence of 15 in the presence of
matched DNA with the largest decrease observed with 12 (33% after one equivalent). In
contrast there was a much more significant luminescence decrease, following the order 12
(55% after one equivalent) > 13 (35%) > 14 (21%), in the presence of mismatched DNA
than for matched DNA (Figure 4). While it was not possible to directly detect the
luminescence of the complexes at room temperature, the competition studies provide
evidence that the complexes preferentially bind to DNA mismatches through their sterically
expansive inserting ligands.
The restoration of luminescence at low temperature for [Ru(bpy)2(chrysi)]2+ (12) and
[Ru(bpy)2(naphthi)]2+ (14) suggests that non-radiative solvent relaxation, most likely
through the exchangeable imino protons, is responsible for the loss of luminescence at
ambient temperature. Preliminary studies have revealed that methylation of the imino
protons of 12 restores luminescence at ambient temperature. However, synthetic difficulties
and decomposition of the methylated complex limited further studies.
Unlike complexes 12 – 14, the [Ru(bpy)2(dppz)]2+ derivatives (15 – 21, Figure 2) all show
enhanced luminescence with matched (M), mismatched (MM), and abasic (AB) DNA versus
in the absence of DNA in aqueous buffer, indicating that the conserved phenazine portion
retains some of the photophysical properties of the parent complex 15 (Figure 5). However,
complexes having extensively π-conjugated ligands (18 – 21) emit luminescence with
detectable intensity in the absence of DNA, possibly due to partial shielding of one of the
phenazine nitrogens from the solvent by the added steric bulk.
Similar to 15, the [Ru(bpy)2(dppa)]2+ complex (16) exhibits luminescence enhancement in
the presence of MM and AB DNA, relative to well-matched DNA, although its binding
affinity is lower than that of 15 (Figure 5 and Table S1). Attachment of a benzo group to the
end of the phenazine moiety increases the length of the dppz-type ligand (dppn, Scheme 2).
We assume binding to the DNAs resemble that of the dppz complex. Significantly,
[Ru(bpy)2(dppn)]2+ (19) exhibits an increase in luminescence with MM over M and AB
DNA (Figure 5). This may be because the extended dppn ligand of 19, when bound to well-
matched DNA from the major groove, offers less protection to the phenazine nitrogens from
solvent water molecules than does dppz. However, for dppn, binding to mismatches likely
occurs from the minor groove as it does for dppz. The minor groove is deep and narrow,
allowing deeper intercalation of the Ru complex and consequently better protection of the
ligand from solvent water.
Introduction of the expansive dppz derivatives dppae and tactp, employing acetylene and
chrysene functionalities respectively to increase the width of the ligand, eliminates the
luminescence differential with DNA defects (Figure 5). In the case of [Ru(bpy)2(tactp)]2+
(18), a previous study demonstrated that luminescence increases not only through interaction
with DNA but also by dimerization or aggregation of the complex itself with or without a
DNA template.8d
Substituents were also incorporated onto dppn to widen this ligand. These derivatives are
Br2dppn and phen-pyrene (Scheme 2), which are both wider and longer than dppz. The Ru
complexes (20 and 21, Figure 2) bearing Br2dppn and phen-pyrene do not show any
differential luminescence between M, MM, and AB DNA, however (Figure 5). The weak
luminescence of 20 may be due to heavy atom quenching by bromine.29 The increased
luminescence of 21 could occur in a manner similar to that of the structural homolog 18, i.e.,
through DNA-templated dimerization.8d
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In sum, the luminescence measurements of 15 – 21 (Figure 2) suggest that structural
modification of dppz is not sufficient to improve specific detection of DNA defects through
the luminescence response of dppz derivatives. The discrepancy between the high specificity
of [Rh(bpy)2(chrysi)]3+ complexes binding to DNA mismatches and the lack of specificity
observed for these dppz derivatives might be due to differences in the proximity of the steric
bulk to the metal center in the respective complexes. In the [Ru(bpy)2(dppz)]2+ derivatives
studied here, the bulky portions of the intercalating ligands are well removed from the metal
center, allowing considerable conformational flexibility of binding. In the case of the Rh
complex, the chrysi ligand is much closer to the metal center, so its binding geometry is
constrained to that imposed by the octahedral center. This notion echoes the conclusions
from a previous study comparing the binding of [Rh(bpy)2(chrysi)]3+ to mismatched DNA
with that of [Ru(bpy)2(eilatin)]2+.30 However, unlike the weakly-emissive eilatin complex,
the dppz derivatives preserve the “light switch” behavior in the presence of DNA.
Excited state lifetimes
The excited state lifetimes also reveal the binding preferences of the complexes. Given that
complexes 12 – 14 (Figure 2) are not luminescent at ambient temperature, their mismatch
specificity was investigated through competition experiments with [Ru(bpy)2(dppz)]2+ (15)
in the presence of matched and mismatched DNA. Luminescence from the dppz complex
decays biexponentially, with each lifetime corresponding to one binding geometry:
perpendicular (longer lifetime) or side-on (shorter lifetime).8,16 Greater protection of the
phenazine moiety from water via intercalation leads to longer emission lifetimes for the two
binding modes (side-on and perpendicular), a higher relative population of the longer-lived
species, or both.
The lifetimes do not change within experimental error in the presence of matched DNA
upon addition of up to two equivalents of complexes 12 – 14, although the relative
population of the longer-lived species decreases (Table 1). This is consistent with a change
in binding mode from perpendicular to side-on and suggests that the small luminescence
decrease observed in the luminescence competition experiments is largely due to a binding
mode change rather than displacement of [Ru(bpy)2(dppz)]2+ (15) from matched DNA.
In the absence of a competing complex, both lifetimes are greater for 1:1 mixture of
[Ru(bpy)2(dppz)]2+ (15) and mismatched DNA compared to well-matched DNA due to
greater protection of the phenazine moiety at the mismatch (Table 1). After the addition of
two equivalents of complexes 12 – 14, both excited state lifetimes decrease and approach
each of the lifetimes of 15 observed in the presence of matched DNA. The magnitude of the
decrease agrees with the steady state luminescence competition experiments where the
largest decrease is observed with 12 followed by 13 and 14. In addition to the lifetime
changes, the relative population of the perpendicular state decreases. These results contrast
those from analogous experiments with matched DNA suggesting that the changes are due
to displacement of 15 from the mismatch rather than a binding mode change. This is further
evidence that the complexes bind preferentially to mismatched DNA over matched DNA.
For the [Ru(bpy)2(dppz)]2+ derivatives (15 – 21, Figure 2), the binding preferences of the
complexes in 2:1 DNA/Ru mixtures could be probed directly at ambient temperature. As
shown in Table 2, 15 displays a higher relative abundance bound in the perpendicular mode
in the presence of DNA following the order AB > MM > M. This supports the observation
from steady state measurements that the luminescence intensity of 15 is present in the
following order: AB > MM > M (Figure 5).16 Likewise, in the case of [Ru(bpy)2(dppa)]2+
(16), longer lifetimes corresponding to the perpendicular mode (AB > MM > M) are
observed, which can explain the trend in the steady state luminescence measurements of 16,
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as shown in Figure 5. Furthermore, [Ru(bpy)2(dppn)]2+ (19), which shows differential
luminescence turn-on with MM over M and AB, indicates longer lifetimes in both binding
modes only with MM. Overall, excited state lifetime measurements indicate that 15, 16, and
19 display longer lifetimes or a higher population in the perpendicular mode in the presence
of DNA containing a lesion, suggesting greater protection of the phenazine nitrogen atoms
upon binding to DNA defects.
The Ru complexes 18 and 21, which can aggregate in the presence of a DNA template,
exhibit single exponential luminescent decays with DNA (Table 2), suggesting that their
luminescence enhancement originates mainly from nonspecific binding to DNA. The Ru
complexes 17 and 20, which have increased steric bulk on the phenazine fragment but utilize
different substituents than 18 and 21, present biexponential decays in emission. Lifetime
measurements show a lower relative yield of long-lived species for 17 and shorter lifetimes
for 20 in the presence of DNA containing defects. These results are consistent with the slight
decrease in steady state luminescence observed for 17 and 20 when combined with DNA
containing defects (Figure 5).
SUMMARY AND IMPLICATIONS
Taking inspiration from the mismatch specificity of the sterically expansive chrysi ligand
and light switch behavior of [Ru(bpy)2(dppz)]2+, a family of Ru(II) complexes was prepared
in an attempt to specifically target DNA defects and indicate their presence by the
appearance of luminescence. In one design strategy, complexes containing sterically
expansive ligands, such as chrysi and analogues with hydrogen bonding functionality similar
to dppz, were synthesized. The incorporation of the sterically expansive ligand appears to
improve the mismatch specificity; however, the complexes are nonluminescent at room
temperature. The exchangeable imino protons most likely quench luminescence at room
temperature through solvent relaxation as luminescence is restored at 77 K for
[Ru(bpy)2(chrysi)]2+ (12) and [Ru(bpy)2(naphthi)]2+ (14). Despite their mismatch
specificity, the lack of luminescence signals at room temperature limits the use of these
complexes as probes. Light switch behavior cannot be exploited at low temperature to
improve mismatch discrimination, as the known “light switch” complex [Ru(bpy)2(dppz)]2+
(15) shows luminescence at 77 K even in the absence of DNA.
The Ru complexes containing dppz derivatives (15 – 21) were also synthesized with the goal
of increasing their steric bulk through the incorporation of various functionalities on the
ligand framework. Their luminescence responses, however, were not substantially enhanced
compared with the parent complex 15 in the presence of DNA with a mismatched or abasic
site. Nevertheless, the narrow ligands (dppa and dppn) show differential luminescence
behavior in the presence of a DNA defect. Widening the dppz ligand using a simple group
such as acetylene or Br does not enhance targeting to destabilized regions of DNA.
Furthermore, the Ru complexes with the extensively π-conjugated ligands (tactp and pyrene-
phen) are likely to aggregate and are therefore unable to report mismatches via luminescence
output.
These observations are consistent with a recent crystal structure in which the dppz ligand of
Δ-[Ru(bpy)2(dppz)]2+ inserts deeply from the minor groove at mismatched sites.14 In the
crystal structure, the central ring of the phenazine portion of dppz stacks with the DNA
bases, affording the nitrogen atoms of the phenazine moiety maximum protection from
solvent water. Considering the structural resemblance between dppa and dppz, complexes of
the two ligands are likely to bind DNA in the same manner. The similarity in mismatch
discrimination between [Ru(bpy)2(dppa)]2+ (16) and [Ru(bpy)2(dppz)]2+ (15) is therefore
not surprising. Extension of dppz to form dppn alters the equilibrium binding geometry of
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the complex. The relatively high mismatch discrimination of the dppn complex may
therefore indicate stronger binding and more effective protection from solvent at
mismatched sites. Similarly, widening the terminal phenazine ring of dppz to form tactp or
pyrene-phen may result in stacking between the DNA bases and these wider, extended
structures, decreasing the degree of protection experienced by the nitrogen atoms of the
phenazine ring. Presumably, these modifications are also responsible for aggregation of the
complexes. Consequently, the phenazine nitrogens in tactp and pyrene-phen may be
similarly accessible to solvent whether the complex is dimerized, intercalated, or inserted;
hence, the tactp and pyrene-phen complexes exhibit similar luminescence profiles with all
three types of DNA.
Of the two approaches investigated here, increasing the steric bulk of the dppz framework
appeared to be more successful, as all of the derivative complexes retained “light switch”
behavior. Although the structural modifications investigated here are not sufficient by
themselves to enhance the luminescence differential between matched and defective DNA,
future efforts to improve the mismatch specificity of [Ru(bpy)2(dppz)]2+ should perhaps
shift away from appending steric bulk to the distal portion of the dppz ligand. The
[Ru(bpy)2(dppz)]2+ scaffold, thus, may be able to withstand the even bolder modifications
necessary to achieve mismatch-specific luminescence.
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Figure 1.
Chemical structures of [Rh(bpy)2(chrysi)]3+ and [Ru(bpy)2(dppz)]2+.
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Figure 2.
Two strategies for designing new Ru complexes.
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Figure 3.
Emission spectra of [Ru(bpy)2(chrysi)]2+ (12) and [Ru(bpy)2(naphthi)]2+ (14) in the
presence and absence of DNA at 77 K and room temperature (10 M LiCl, λex = 440 nm).
[Ru] = 5 µM, [DNA] = 0 or 5 µM. The DNA sequences are shown at the top of the figure.
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Figure 4.
Plots of the integrated emission intensity of 0.1 µM [Ru(bpy)2(dppz)]2+ (15) and 0.1 µM
matched (M) or mismatched (MM) DNA with up to 10 equivalents of [Ru(bpy)2(L)]2+
where L is chrysi (12), acri (13) or naphthi (14) (5 mM Tris, pH 7.5, 50 mM NaCl, λex = 440
nm). See Figure 3 for the DNA sequences.
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Figure 5.
Plots of the integrated emission intensity of 15 – 21 with matched (M), mismatched (MM),
and abasic (AB) DNA (5 mM Tris, pH 7.5, 50 mM NaCl, λex = 440 nm). [Ru] = 0.1 µM (for
15, 18, and 21), 1 µM (for 16 and 17), 5 µM (for 19), and 10 µM (for 20). DNA sequences
are depicted (top, left).
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Scheme 1.
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Scheme 2.
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Scheme 3.
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Table 2
Luminescence Decay Parameters for the [Ru(bpy)2(dppz)]2+ Complexes in the Presence of Matched (M),
Mismatched (MM), and Abasic (AB) DNAa
Complex (Ligand) No DNA In the presence of DNA
τ(ns)b,c DNA τ1, ns (%)c τ2, ns (%)c
15 (dppz) 180d M     72 (83)   210 (17)
MM     74 (77)   210 (23)
AB     86 (69)   190 (31)
16 (dppa) 190 M     32 (95)   190 (5)
MM     32 (96)   250 (4)
AB     26 (93)   540 (7)
17e (dppae) 190 M   280 (60) 3900 (40)
MM   390 (67) 4280 (33)
AB   500 (62) 4640 (38)
18 (tactp) 210 M 1210 (100)
MM 1180 (100)
AB 1120 (100)
19 (dppn) 170 M     62 (51)   840 (49)
MM   200 (49) 1010 (51)
AB     35 (58)   710 (42)
20 (Br2dppn) 200 M     99 (63) 1060 (37)
MM   130 (66)   880 (34)
AB     82 (54)   800 (46)
21 (pyrene-phen) 190 M   930 (100)
MM   880 (100)
AB   810 (100)
aλex = 470 nm, λem = 610 nm, 10 µM [Ru] and 20 µM [DNA] (5 mM Tris, pH 7.5, 50 mM NaCl). The matched (M), mismatched (MM) and
abasic (AB) oligonucleotides in Figure 5 were used. Emission decays were fit to the monoexponential function Y(t) = Y0 + A1*exp(−t/τ1) or
biexponential function Y(t) = Y0 + A1*exp(−t/τ1) + A2*exp(−t/τ2) to give the lifetimes τ1 and τ2. The relative contribution of each lifetime to
the overall decay is indicated in parentheses.
b[Ru] = 10 µM, CH3CN.
c
Error is estimated to be ±10%.
d
reference 8.
e20 µM [Ru] and 40 µM [DNA].
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